Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty

QINGWEI RUAN1*, GRAZIA D’ONOFRIO2*, DANIELE SANCARLO2, ANTONIO GRECO2 and ZHUOWEI YU1

1Shanghai Institute of Geriatrics and Gerontology, Shanghai Key Laboratory of Clinical Geriatrics, Department of Geriatrics, Huadong Hospital, and Research Center of Aging and Medicine, Shanghai Medical College, Fudan University, Shanghai 200040, P.R. China; 2Geriatric Unit & Laboratory of Gerontology and Geriatrics, Department of Medical Sciences, IRCCS ‘Casa Sollievo della Sofferenza’, San Giovanni Rotondo, I-71013 Foggia, Italy

Received February 22, 2016; Accepted July 18, 2016

DOI: 10.3892/mmr.2016.5618

Abstract. Cognitive frailty (CF) overlaps with early neuro-pathological alterations associated with aging-related major neurocognitive disorders, including Alzheimer's disease (AD). Fluid biomarkers for these pathological brain alterations allow for early diagnosis in the preclinical stages of AD, and for objective prognostic assessments in clinical intervention trials. These biomarkers may also be helpful in the screening of CF. The present study reviewed the literature and identified systematic reviews of cohort studies and other authoritative reports. The selection criteria for potentially suitable fluid biomarkers included: i) Frequent use in studies of fluid-derived markers and ii) evidence of novel measurement techniques for fluid-derived markers. The present study focused on studies that assessed these biomarkers in AD, mild cognitive impairment and non-AD demented subjects. At present, widely used fluid biomarkers include cerebrospinal fluid (CSF), total tau, phosphorylated tau and amyloid-β levels. With the development of novel measurement techniques and improvements in understanding regarding the mechanisms underlying aging-related major neurocognitive disorders, numerous novel biomarkers associated with various aspects of AD neuropathology are being explored. These include specific measurements of Aβ oligomer or monomer forms, tau proteins in the peripheral plasma and CSF, and novel markers of synaptic dysfunction, neuronal damage and apoptosis, neuronal activity alteration, neuroinflammation, blood brain barrier dysfunction, oxidative stress, metabolites, mitochondrial function and aberrant lipid metabolism. The proposed panels of fluid biomarkers may be useful in the early diagnosis of AD, prediction of the progression of AD from preclinical stages to the dementia stage, and the differentiation of AD from non-AD dementia. In combination with physical frailty, the present study surmised that these biomarkers may also be used as biomarkers for CF; thus contribute to discovering causes and informing interventions for cognitive impairment in individuals with CF.

Introduction

Cognitive frailty (CF) refers to a heterogeneous clinical syndrome found in elderly individuals that excludes those with AD and other types of dementia, and is characterized by concurrent physical frailty and potentially reversible cognitive impairment (1). CF includes reversible and potentially reversible subtypes (2), and may represent a precursor to neurodegenerative processes. Although studies regarding CF biomarkers are scarce, the neuropathological processes overlap with those in individuals with AD and/or other neurodegenerative diseases, and the final outcomes of CF are AD or non-AD dementia. Therefore, excluding biomarkers of physical frailty, other biomarkers, such as amyloid-β (Aβ) accumulation, neurodegeneration or neuronal injury, may be considered biomarkers for CF. Reversible CF occurs in the later stages of preclinical AD or at the pre-mild cognitive impairment (MCI) stage due to other causes, and can be diagnosed based on subjective cognitive decline (SCD) and/or positive biomarkers. Cognitive impairment in potentially reversible CF is comparable to MCI.

Diagnosis of preclinical sporadic AD or other suspected non-Alzheimer pathologies in reversible CF depends on the evidence of pathophysiological alterations in the brain, as demonstrated by established fluid and imaging biomarkers. Neuronal injury or neurodegeneration-associated biomarkers offer chances to predict cognitive impairment progression and prognosis, and to evaluate outcomes of disease-modifying...
interventions in clinical trials (3). However, there are several challenges, including invasive or expensive detection techniques, and time-consuming detection procedures for the measurement of current biomarkers for disease-induced early neuropathological alterations. The most important challenges associated with current biomarkers are the measurement techniques; for example, current standard enzyme-linked immunosorbent assay (ELISA) methods are insensitive to very low concentrations of biomarkers in cerebrospinal fluid (CSF) and blood (4). Therefore, blood- and urine-based biomarkers may be more attractive biomarkers for the screening of neuropathological alterations in AD and CF. The present study systematically reviewed the advance of fluid biomarkers for the pathological process of AD, which will likely aid in the discovery of biomarkers for CF.

Materials and methods

Literature search. The search strategy was updated according to best practice recommendations (5,6). Literature searches were performed using MEDLINE (between 1996 and April 2015; https://www.nlm.nih.gov/bsd/pmrresources.html) and PubMed (between 1990 and November 2015; www.ncbi.nlm.nih.gov/pubmed) databases. The search queries included: i) Blood, ii) cerebrospinal fluid, iii) urine, iv) Alzheimer’s disease and v) mild cognitive impairment.

Study selection. A reviewer scrutinized abstracts found by electronic search in order to identify articles meriting a full review. Entire articles were reviewed before data were extracted from pertinent papers.

The inclusion criteria used for the review protocol were as follows: i) Age ≥60 years, ii) diagnosis of AD according to the criteria of the National Institute on Aging-Alzheimer’s Association (NIAAA) (7) or diagnosis of MCI according to NIAAA criteria (8) with a confirmed progression to AD assessed by clinical follow-up, and iii) suitable clinical assessments of cognitive and functional impairment, quality of life and clinical evaluations. The exclusion criteria were: i) No English editing (as we lacked resources for translation), ii) diagnosis of non-AD dementia, and iii) MCI that did not progress to AD. No limits were defined on the grounds of disease duration or drug treatment.

Data extraction. A total of 2,243 papers, and 92 additional articles from recent reviews were found. After reviewing the abstracts, 648 papers were obtained on the basis of the aforementioned inclusion/exclusion criteria and duplicates. After screening, 259 papers were reserved, of which 36 reviews and 158 full-text articles were excluded after more in-depth examination, on the basis of the same inclusion/exclusion criteria. Therefore, 65 published studies were considered eligible for the current review (Fig. 1). Data extraction was divided into four categories among the authors by expertise: Potential blood-derived markers of AD and MCI, potential CSF-derived markers of AD and MCI, potential urinary-derived markers of AD and MCI, and cell-based techniques for analyzing tau pathogenicity. Co-authors provided a detailed abstract of all studies describing their strengths and weaknesses, as well as a general evaluation of the category (9,10). The quality of studies was assessed using the Standards for the Reporting of Diagnostic Accuracy Studies in dementia (11).

Results and Discussion

Potential blood-derived markers of AD and MCI. The potential blood-derived biomarkers for AD and MCI are presented in Table I. The ratio of amyloid precursor protein (APP) forms contained in the platelets was significantly decreased in individuals with mild AD, very mild AD and MCI (12), individuals with MCI that progressed to AD dementia (13), and patients with AD that exhibited cognitive decline (14). Compared with patients with non-amnestic MCI, patients with amnestic MCI exhibited increased levels of coated-platelets, which are produced by collagen and thrombin activation. In addition, the increases in coated-platelet levels were associated with an increased risk for the progression to AD (15). There were significantly lower levels of Aβ1-42 and Aβ1-42/1-40 in the plasma of patients with AD compared with patients with non-AD dementia, or in patients with AD-type MCI compared with patients with other types of MCI (16). A cross-sectional study demonstrated that plasma Aβ1-40 levels were independently associated with microvascular brain injury (17). However, plasma Aβ peptide levels only weakly predicted the conversion to AD in normal individuals (18). In addition, plasma Aβ monomer biomarkers were not sensitive enough to discriminate patients with AD-type MCI from patients with early AD, or to distinguish patients with other types of MCI from patients with other types of early dementia.

Tau proteins in the serum are potential biomarkers for neuronal degeneration or damage. A novel ultrasensitive digital immunoassay technology, which is referred to as a single-molecule ELISA, is able to detect clinically relevant proteins in the serum at concentrations <10⁻¹² M (19). Compared with the classic ELISA, this ultrasensitive technique is 1,000-fold more sensitive. The lower limit of quantification is 0.02 pg/ml, which is 100 times higher than the plasma levels of tau proteins (~5 pg/ml). This ultrasensitive technique has detected dynamic changes in tau protein in the serum after hypoxic brain injury, and a mean 2-fold increase in AD individuals, however with some overlaps with the levels in patients with MCI and the controls (20). However, rare protein isoforms that result due to cleavage of the tau protein and disease-specific tau phosphorylation are not recognized by currently available assays (21).

Aberrant lipid metabolism is associated with the pathophysiological processes in AD. Some plasma phospholipids may therefore be considered biomarkers for AD. Reductions in the levels of these phospholipids may accurately predict the progression of an individual from normal cognition to MCI or AD within 2 years (22,23). A biomarker panel that detected decreases in the levels of 10 phospholipids in blood plasma that reflect cell membrane integrity may be able to predict which cognitively normal elderly adults will develop MCI and AD with >90% accuracy (22). Early studies have reported that phosphatidylcholine molecules in AD brains are decreased and that their main metabolite, glycerophosphocholine, is increased (23,24). However, some phosphatidylcholines produced by the sequential methylation of another phosphatide, such as phosphatidylethanolamine, were increased in
| Study                  | Methods                          | Identified biomarkers                                                                 | AD (n) | MCI (n) | Control (n) | Refs. |
|-----------------------|----------------------------------|---------------------------------------------------------------------------------------|--------|---------|------------|-------|
| Borroni *et al*, 2003 | Western blot analysis            | Decreased baseline platelet APP predicted progression from MCI to AD                 | -      | 30      | -          | 13    |
| Zetterberg *et al*, 2013 | Tau5, HT7 and BT2 monoclonal antibodies | Higher tau levels in AD                                                               | 54     | 75      | 25         | 20    |
| Zhang *et al*, 2014   | Post-mortem autopsy              | Deletion of the AEP gene substantially reduced tau hyperphosphorylation              | 8      | -       | 8          | 21    |
| Mapstone *et al*, 2014 | LASSO analysis                   | ApoE ε4 was similar in MCI and AD                                                    | 18     | 35      | 53         | 22    |
| Whiley *et al*, 2014  | LC-MS and MLV                    | Three PCs were significantly lower in AD                                              | 75     | 82      | 84         | 23    |
| Marksteiner *et al*, 2014 | Multiplex array or ELISA       | 27 vascular-related proteins; NT-proBNP was significantly increased in AD and MCI   | 43     | 27      | 40         | 25    |
| Hye *et al*, 2014     | Multiplex (xMAP) assays          | 10 plasma proteins (ApoC3, TTR, A1AT, PEDF, CC4, ICAM-1, RANTES, A1AcidG, cystatin C, clusterin) were associated with disease severity and progression | 476    | 220     | 452        | 26    |
| Lane *et al*, 2008    | ELISA, MRI                       | MCI with ApoE ε4 and BCHE-K progressed to AD                                          | -      | 464     | -          | 27    |
| Soares *et al*, 2012  | Multiplex immunoassay panel      | Increases in eotaxin 3, pancreatic polypeptide, NT-proBNP and TN-C; decreases in IgM and ApoE levels in patients with AD and MCI; Apo ε3/ε4 or ε4/ε4 carriers had low C-reactive protein and Apo levels, and high cortisol, interleukin-13, apolipoprotein B and gamma interferon levels | 97     | 345     | 54         | 28    |
| Sattlecker *et al*, 2014 | SOMAscan                        | PSA-ACT, pancreatic prohormone, clusterin and fetuin B were related to AD            | 331    | 149     | 211        | 29    |
| Craig-Schapiro *et al*, 2010 | 2-D DIGE LC-MS/MS and ELISA      | YKL-40, a putative indicator of neuroinflammation, is elevated in AD, and together with Aβ42, has potential prognostic use as a biomarker for preclinical AD | 48     | -       | -          | 31    |
| Mangialasche *et al*, 2013 | HPLC                            | Vitamin E measures enhanced the accuracy of sMRI differentiating patients with AD and MCI from cognitively healthy subjects | 81     | 86      | 86         | 33    |
| Squitti *et al*, 2009 | Spectrophotometry and immunoturbidimetry assay | Higher baseline levels of free copper were correlated with severe cognitive decline in AD and more obvious disabilities at 1 year | 81     | -       | -          | 36    |
| Pavlopoulos *et al*, 2013 | Post-mortem human autopsy and mouse study | RbAp48 decline is responsible for age-related memory loss | 8      | -       | -          | 37    |
| Nettiksimmons *et al*, 2015 | ELISA and INNO-BIA assays        | Higher risk index of blood markers (telomere length, cystatin, serum glucose, C-reactive protein, albumin, IL-6, ApoE ε4 and Aβ42/40) exhibited severe cognitive decline | -      | -       | 739        | 39    |
Table I. Continued.

| Identified biomarkers | Methods | Study | AD | MCI | Control | Refs. |
|-----------------------|---------|-------|----|-----|---------|-------|
| apoE genotype, plasma levels of IL-6R and clusterin | Luminex, quantitative polymerase chain reaction | Apostolova et al., 2015 | - | 211 | - | 40 |
| apoE genotype | ELISA, enzyme-linked immunosorbent assay | | | | | |
| plasma levels of IL-6R and clusterin | Somatic Cancer Array Technology (SOMAscan) | | | | | |
| APOE ε4 genotype, plasma levels of IL-6R and clusterin | Multiplex assays | | | | | |

AD brains. It has previously been demonstrated that three phosphatidylycholine molecules were significantly diminished in patients with AD compared with patients with MCI or age-matched individuals (23).

A previous study measured the plasma levels of 27 vascular-related proteins using multiplex assays or ELISA in patients with MCI or AD, and in healthy controls. The results indicated that N-terminal pro-brain natriuretic peptide (NT-proBNP) was significantly increased in patients with MCI or AD, and could be considered a potential biomarker for AD diagnosis and prognosis (25). Multiplex assays were used to measure 26 previously discovered AD-associated plasma biomarkers in plasma samples from patients with AD and MCI, and elderly non-demented individuals from three multicenter cohorts. These assays demonstrated that 10 proteins, namely transthyretin (TTR), clusterin, cystatin C, alpha-1-acid glycoprotein, intercellular adhesion molecule 1, complement C4, pigment epithelium-derived factor (PEDF), alpha-1-antitrypsin, normal T cells, and expressed and secreted Apolipoprotein C3, were strongly associated with the severity and progression of AD. The 10 proteins, plus the Apolipoproteina E (ApoE) genotype, had the greatest predictive power for identifying dementia from prodromal disease (26). In addition, butyrylcholinesterase K-variant alleles had synergistic effects with the APOE ε4 genotype on the conversion of MCI to AD (27).

Another study measured the levels of 146 plasma proteins at baseline and after 1 year using a multiplex immunoassay panel; the results verified that the levels of eotaxin 3, pancreatic polypeptide and NT-proBNP were increased in subjects with AD and MCI, which was similar to changes detected in the CSF, and also demonstrated that the Apo ε3/ε4 or ε4/ε4 genotype depended on the biochemical profile (28). Another study quantified 1,001 proteins by SOMAscan, and demonstrated that protein expression levels of prostate-specific antigen complexed to α1-antichymotrypsin, pancreatic prohormone, clusterin and fetuin B were the most strongly associated with AD. Pancreatic prohormone was significantly associated with left entorhinal cortex and hippocampus atrophy, whereas fetuin B was only related to left entorhinal atrophy. Clusterin was significantly related to the rate of cognitive decline (29).

Other potential blood-derived markers include mitochondrial function indicator N-acetylaspartate (NAA), neuroinflammatory indicator chitinase-3-like 1 (YKL-40), stress protein heme oxygenase-1 (HO-1), nutritional biomarkers, histone-binding protein RbAp48, plasma ketone body (KB), and a cumulative risk index based on several pathways associated with cognitive decline for blood-derived markers. NAA levels are coupled to neuronal mitochondrial function and are correlated with Aβ42 in patients with AD (30). The mean plasma and CSF levels of YKL-40 were enhanced in individuals with a clinical dementia rating between 0.5 and 1, and YKL-40 is considered a potential fluid biomarker for preclinical AD (31). HO-1 protein levels in plasma and CSF; and mRNA levels of lymphocyte HO-1 in individuals with sporadic AD are decreased compared with in normal controls, and other subjects with chronic neurological and medical disorders (32). A previous study suggested that plasma levels of α-γ-tocopherols, or plasma levels of γ-tocotrienols in combination with structural magnetic resonance imaging (sMRI) measures, may be used to differentiate patients with...
AD or MCI from cognitively healthy individuals, and predict the conversion of MCI to AD after 1 year of follow-up (33). High levels of homocysteine, a risk factor for microvascular impairment, have been associated with alterations in electroencephalographic rhythms in mild AD, but not in MCI subjects, including unselective increases in cortical delta, theta and alpha rhythms (34). Compared with control individuals, plasma levels of non-enzymatic and enzymatic antioxidants were similarly decreased in patients with MCI and AD (35). Baseline higher levels of free copper may be used to predict severe cognitive decline in AD, and a faster and more obvious progression of disability at 1 year (36). Patients with higher levels of free copper combined with hyperlipidemia were also prone to severe cognitive impairment. RbAp48 modifies histone acylation and is associated with age-related memory impairment. Post-mortem measures demonstrated that levels of RbAp48, which are associated with hippocampus-dependent memory deficits in elderly individuals, were decreased in the dentate gyrus. Similar memory deficits were also observed in RbAp48-deficient transgenic mice (37). Unlike the amyloid cascade hypothesis, which suggests that amyloid pathways are the main therapeutic target, the interventions based on the mitochondrial cascade hypothesis, which suggests that mitochondrial function decline triggers AD pathophysiological cascade, are associated with the restoration and maintenance of mitochondrial function. The increase in plasma KB levels induced by ketone ester in several animal models of AD may improve mitochondrial metabolism and postpone the appearance of AD-like pathological alterations (38). Therefore, low plasma KB levels may be a potential biomarker for AD pathology in individuals with preclinical sporadic AD or reversible CF. A cumulative risk index, including blood-derived markers ApoE ε4 and Aβ42/40, telomere length, blood glucose, cystatin, C-reactive protein, interleukin (IL)-6 and albumin (39), may provide valuable predictive information regarding future cognitive trajectories independent of age and baseline cognitive status. It is a question worthy of further research whether this same risk index could also predict CF. In addition, the ApoE genotype, IL-6 receptor and clusterin plasma levels, together with Auditory-Verbal Learning Test and Trails B have been reported to be useful for predicting brain amyloidosis and MCI progression to AD with modest accuracy (40). In genetic analyses of non-familial AD, the ApoE ε4 genotype contributes to the heterogeneity of disease processes associated with sporadic AD (41-43). In addition, alongside the ApoE receptor, the low density lipoprotein receptor 5 repeated allele has been reported to be associated with the risk of dementia, and the correlation was more evident in individuals with mixed or vascular dementia (VaD) compared with AD (44).

**Potential CSF-derived markers of AD and MCI.** The CSF-derived biomarkers for AD and MCI are presented in Table II. The monomer form Aβ42, tau and phosphorylated (p)-tau are widely used to screen AD and MCI caused by AD, and to predict the conversion of preclinical AD and MCI to AD (45,46), independent of the ApoE genotype (43). Among the CSF biomarkers, CSF Aβ42 has been reported to have the best diagnostic accuracy for the discrimination of AD from frontotemporal dementia (47). CSF Aβ42 and florbetapir were inversely correlated across cognitively normal, MCI and AD groups with 86% consistency (48). Abnormal CSF Aβ levels together with abnormal imaging and serum markers exhibited a better predictive value for the earliest stage of AD (49). Individuals with abnormal CSF proteins, particularly abnormalities of both tau and Aβ42 appeared to be simultaneously at greatest risk of cognitive decline (50) and progression from MCI into incipient AD (51). In addition, the p-tau/Aβ42 ratio
Table II. CSF-derived markers for identifying the risk of MCI and AD.

| Studies                  | Methods                                      | Identified biomarkers                                                                 | AD (n) | MCI (n) | Control (n) | Refs. |
|--------------------------|----------------------------------------------|---------------------------------------------------------------------------------------|--------|---------|-------------|-------|
| Lautner et al, 2014      | ELISA                                        | Low CSF Aβ in AD and MCI was independent of ApoE genotype                             | 309    | 287     | 251         | 43    |
| Riemenschneider et al, 2002 | ELISA                                        | Aβ42 levels were significantly decreased in patients with MCI that progressed to probable AD and those with progressive MCI compared with subjects with stable MCI | 10     | 28      | -           | 45    |
| Ewers et al, 2015        | Multiplex Xmap, luminex platform             | CSF Aβ42 exhibited the best diagnostic accuracy to discriminate AD from FTD, but showed significant overlap with other types of NAD dementia | 167    | 172     | 55          | 47    |
| Landau et al, 2013       | Multiplex xMAP, luminex and Florbetapir image| CSF and amyloid-PET measurements of Aβ were consistent in 86% subjects; CSF Aβ abnormality was not regularly detected prior to fibrillar Aβ accumulation | 22     | 249     | 103         | 48    |
| Nettiksimmons et al, 2010 | TaqMan, multiplex Xmap, luminex platform, sMRI | CSF proteins, together with MRI and ApoE ε4, allele may represent the earliest stages of AD | -      | -       | 112         | 49    |
| Okonkwo et al, 2010      | Multiplex Xmap, luminex platform, PFAQ       | Abnormal CSF levels of t-tau, p-tau and Aβ42 predicted functional decline and the conversion from control and MCI to AD, but not further prognosis in patients with AD | 100    | 195     | 114         | 50    |
| Mattsson et al, 2009     | ELISA                                        | CSF Aβ42, t-tau, and p-tau could identify incipient AD with good accuracy in patients with MCI | 529    | 750     | 304         | 51    |
| Laudau et al, 2010       | ELISA                                        | P-tau-t181p/Aβ_1-42 predicted longitudinal cognitive decline                           | -      | 85      | -           | 52    |
| Van Rossum et al, 2012   | ELISA                                        | The injury markers CSF t-tau and p-tau and hippocampal atrophy could predict further cognitive decline | -      | 110     | -           | 53    |
| Vemuri et al, 2009       | STAND                                        | T-tau, p-tau and Aβ42 provided better predictive values than either source alone with regards to the conversion from aMCI to AD | 98     | 192     | 109         | 54    |
| Eckerström et al, 2013   | ELISA, sMRI                                  | The combination of CSF Aβ42, t-tau, and p-tau, neuropsychological tests and sMRI was the best predictor of dementia | -      | 21      | 26          | 55    |
| Shaffer et al, 2013      | xMAP luminex platform                        | Combination of imaging and CSF biomarkers could improve the prediction of conversion from MCI to AD | -      | 97      | -           | 56    |
| Vemuri et al, 2010       | Multiplex Xmap, Luminex platform, sMRI       | There was no significant average change in CSF biomarkers except t-tau; ApoE ε4 genotype did not influence the changes in CSF biomarkers | 71     | 149     | 92          | 58    |
| Sutphen et al, 2015      | ELISA, PET + PiB                             | Longitudinal CSF biomarker patterns consistent with AD were first detectable during early middle age, and were associated with later amyloid positivity and cognitive decline | -      | -       | 169         | 85    |

MCI, mild cognitive impairment; AD, Alzheimer's disease; CSF, cerebrospinal fluid; ELISA, enzyme-linked immunosorbent assay; Aβ, amyloid-β; STAND, structural abnormality index; t-, total; p-, phosphorylated; aMCI, amnestic MCI; sMRI, structural magnetic resonance imaging; ApoE, apolipoprotein E; PFAQ, Pfeffer Functional Activities Questionnaire; PET, positron emission tomography; FTD, frontotemporal dementia; NAD, non-Alzheimer's disease; PiB, Pittsburgh compound B.
in CSF could longitudinally predict cognitive performance loss in subjects with MCI (52). Injury markers in CSF, including total-tau and p-tau, could also predict conversion time, from MCI with amyloid pathology, to dementia (53). However, MRI was slightly better at predicting future clinically defined disease stages and functional decline compared with Aβ42, tau or p-tau in the CSF (54). A combination of MRI or fluorodeoxyglucose-positron emission tomography and CSF promote the predictive value of the conversion of MCI to AD (55,56). However, a combination of CSF t-tau/Aβ42 together with sMRI or neuropsychological tests was not superior, as compared with single trail making test-B or sMRI measures of the right entorhinal cortex (57). Unlike the evaluated CSF values of t-tau, p-tau and Aβ42, the order of the annual increase in ventricular volume detected by serial sMRI was AD group>amnestic MCI group>no AD group. Furthermore, the annual increase in ventricular volume was consistent with the annual decrease in general cognitive and functional indices. The alterations in structure and cognitive function were influenced by the ApoE ε4 genotype (58).

The potentially associated CSF-derived biomarkers for AD and MCI are presented in Table III. A previous study reported that the albumin ratio between CSF and serum is normal in patients with AD independent of age, and is increased in patients with cerebrovascular diseases (59). However, an elevation in the ratio was associated with AD and VaD in an 85-year-old population, and was associated with the conversion from non-dementia to dementia across 3 years of follow-up (60). A previous study indicated that age-dependent elevation in the ratio could be observed in ApoE ε4 allele carriers without cognitive impairment (61). An elevation in the albumin ratio was also closely associated with severity in patients with AD with medial temporal atrophy (62). Another study demonstrated that an age-dependent elevation in the ratio could only be detected in the hippocampal CA1 and dentate gyrus regions of cognitively normal subjects (63). Compared with cognitively normal subjects, patients with MCI exhibited an increase in the ratio and the levels of soluble platelet-derived growth factor receptor-β. These biomarkers of neurovascular unit damage appeared earlier than other biomarkers, including CSF Aβ42 and tau. Increased CSF β-secretase (BACE 1) activity in individuals with sporadic AD may be involved in the amyloidogenic process and axonal degeneration (64). Elevated BACE 1 activity in subjects with AD and MCI has been shown to be associated with the ApoE ε4 genotype, and decreased levels of Aβ42 were only observed in ApoE ε4 carriers with MCI (65). CSF levels of the soluble amyloid precursor proteins (sAPP) α and β were similar between AD and healthy controls; however, sAPP β levels were significantly higher in patients with MCI compared with healthy controls (66). Significantly higher levels of sAPP in the CSF were superior to significantly lower levels of CSF Aβ42 with regards to early prediction of the progression from MCI to AD, and the differential diagnosis of AD from MCI and frontotemporal dementia (67). Compared with the stable MCI group and the control group, the levels of sAPP α and β were significantly higher in the AD group and the MCI progression to AD group; the ApoE ε4 allele had no effects on the levels of sAPP α and β (68). CSF Aβ42/Aβ40 values were more sensitive than CSF levels of Aβ42 for the identification of incipient AD in MCI individuals (69). Soluble Aβ oligomers are potential biomarkers for AD; however, compared with the changes in CSF Aβ42 or tau, changes in the levels of soluble oligomers were not superior for the discrimination of AD from controls (70,71). In a comparative study of brain expression of soluble Aβ oligomers, Aβx56, and Aβ trimers and dimers, it was demonstrated that levels of Aβ dimers were highest in subjects with probable AD, and the levels of Aβx56 and Aβ trimers were lowest when compared with age-matched unimpaired and young unimpaired subjects (72). Furthermore, only Aβx56 was correlated with pathological tau proteins and postsynaptic proteins. These results suggested that Aβx56 may contribute to the very early stages of AD pathogenesis. Savage et al reported that higher Aβ oligomer levels predicted more severe dementia (73). However, analogous to the detection of various monomer forms, including Aβ40 and Aβ42, developing even more specific assays to measure the precise nature of oligomers via more sensitive amplification platforms will improve the early diagnostic potential of these biomarkers (74). The amide I band reflects the structural destruction of all types of Aβ peptides. Its downshift in CSF and blood has been detected in patients with MCI that progressed to AD, and its downshift frequency was superior to a single Aβ misfold or the level of specific oligomers (75).

Synaptic biomarkers in the CSF are potential early biomarkers for AD. Neurogranin, which is mainly located in dendritic spines, is associated with long-term potentiation and memory consolidation. CSF neurogranin is composed of a series of C-terminal peptides. All neurogranin peptides detected by the ELISA method suggest that CSF neurogranin may be used to monitor synaptic degeneration and reflect the rate of cognitive decline in individuals with prodromal AD (76). Even if it is very rare in CSF, the levels of CSF neurogranin peptide 48-76 exhibit the most obvious increase in patients with AD. A progressive decline in CSF levels of neurogranin could be observed from individuals with AD, MCI that progressed to AD, stable MCI to controls (77). Patients with AD or MCI that progressed to AD demonstrated significantly higher baseline CSF levels of neurogranin compared with stable MCI or controls (77,78). CSF levels of the cytoskeleton light neurofilament protein were significantly higher in patients with late-onset AD or frontotemporal dementia compared with controls (79). In addition, alterations in the CSF levels of axonal growth-associated protein-43 were associated with changes in CSF tau and sAPP levels, and patients with AD exhibited a significant increase compared with controls (80). However, the detection of specific peptides and other biomarkers for synaptic dysfunction will benefit from the development of novel ultrasensitive assays.

The onset of cognitive decline is estimated to lag AD pathology by 10-15 years. By the time of the appearance of clinically detectable cognitive impairment, substantial neuronal loss has occurred. As a marker of neuronal damage, the AD-associated neuronal thread protein AD7c-NTP is a ~41 kD membrane-spanning phosphoprotein. The increase in immunoreactive AD7c-NTP in the brain is associated with the increase in p-tau-immunoreactive cytoskeletal lesions, but not the increase in Aβ accumulation. The protein may be involved in neuronal apoptosis and neurite sprouting, and in the pathological alterations of AD. Dying cells in the brain are
Table III. Potential associated CSF-derived markers for identifying risk of MCI and AD.

| Studies                  | Methods         | Identified biomarkers                                                                 | AD (n) | MCI (n) | Control (n) | Refs. |
|--------------------------|-----------------|---------------------------------------------------------------------------------------|--------|---------|-------------|-------|
| Ewers et al, 2012        | ELISA           | The ApoE ε4 genotype was related to increased BACE 1 activity in AD and MCI subjects  | 60     | 51      | 37          | 57    |
| Blennow et al, 1990      | ELISA           | BBB disturbance is not associated with AD and age, but is associated with vascular factors | 118    | -       | 50          | 59    |
| Skoog et al, 1998        | ELISA           | Significantly higher CSF/serum albumin levels were detected in AD, VaD and women that developed dementia | 13     | -       | 29          | 60    |
| Matsumoto et al, 2007    | ELISA           | BBB disturbance was related to MTLA, but not to Aβ transport across the BBB            | 42     | -       | -           | 62    |
| Zetterberg et al, 2008   | Multiplex assay | Higher BACE 1 activity in AD and in MCI that progressed to AD                         | 87     | 113     | 33          | 64    |
| Olsson et al, 2003       | ELISA           | The levels of sAPP α and β did not change between AD and healthy controls, but sAPP β significantly increased in patients with MCI compared to healthy controls | 81     | 19      | 42          | 66    |
| Perneczky et al, 2011    | ELISA           | The levels of sAPP β in the MCI-AD group were significantly higher than in the MCI-NAD and FTD groups | 21     | 58      | 8           | 67    |
| Lewczuk et al, 2012      | Multiplex assay | The levels of sAPP α and β were significantly higher in the AD and MCI-AD groups compared with the MCI-NAD and control groups; ApoE ε4 allele did not affect the levels of sAPP α and β | 88     | 71      | 155         | 68    |
| Hansson et al, 2007      | ELISA + N-terminal monoclonal antibody (82E1) | Aβ42/Aβ40 ratio was superior to Aβ42 concentration with regards to identifying incipient AD in MCI | -      | 137     | -           | 69    |
| Hölttä et al, 2013       | ELISA + N-terminal monoclonal antibody (82E1) | Higher concentrations of Aβ oligomers in the CSF of AD individuals | 199    | 165     | 148         | 70    |
| Herskovits et al, 2013   | ELISA + luminex platform | Higher concentrations of Aβ oligomers in the CSF of AD individuals | 20     | -       | 19          | 71    |
| Savage et al 2014        | ELISA           | Correlation between Aβ40 and oligomers in AD                                           | 63     | -       | 54          | 73    |
| Yang et al, 2015         | ELISA           | Higher concentrations of Aβ oligomers in CSF of AD                                     | 10     | 10      | 10          | 74    |
| Kvartsberg et al, 2015   | Mass spectrometry and ELISA | High CSF Ng levels in AD and MCI                                                      | 100    | 40      | 80          | 76    |
| Portelius et al, 2015    | In-house immunoassay | Levels of neurogranin were AD>MCI-AD>stable MCI>controls                             | 95     | 173     | 110         | 77    |
| Kester et al, 2015       | A sandwich immunoassay | Baseline CSF levels of neurogranin were significantly higher in patients with AD and MCI that progressed to AD compared to controls | 65     | 61      | 37          | 78    |
| Sjögren et al, 2000      | ELISA           | NFL levels of late-onset AD and FTD were significantly increased compared with controls, which may reflect white matter degeneration | 21     | -       | 18          | 79    |
| Sjögren et al, 2001      | ELISA           | CSF levels of GAP 43 correlated with CSF-tau and sAPP and were significantly increased in AD compared with controls | 47     | -       | 12          | 80    |
| de la Monte et al, 1997  | Quantitative enzyme-linked sandwich immunoassay | Clinical and post-mortem CSF levels of AD7c-NTP are related to AD neurodegeneration and the severity of dementia | 17     | -       | 11          | 81    |
| Studies            | Methods                                      | Identified biomarkers                                                                 | AD (n) | MCI (n) | Control (n) | Refs. |
|--------------------|----------------------------------------------|--------------------------------------------------------------------------------------|--------|---------|-------------|-------|
| Tarawneh et al, 2011 | sMRI, Amyloid imaging with PC-B              | CSF VILIP-1/Aβ42 predicted future cognitive impairment at least as well as tau/Aβ42 and p-tau181/Aβ42 | 98     | -       | 211         | 82    |
| Tarawneh et al, 2012 | ELISA                                        | CSF VILIP-1 and VILIP-1/Aβ42 predicted rates of global cognitive decline similar to tau and Aβ42 | 60     | -       | -           | 83    |
| Tarawneh et al, 2015 | ELISA                                        | CSF VILIP-1 levels predict rates of whole-brain and regional atrophy similar to tau and p-tau181 | 23     | -       | 64          | 84    |
| Czech et al, 2012    | GC-MS and LC-MS/MS                          | Increased cortisol levels seemed to be related to the progression of AD; increased cysteine associated with decreased uridine was the best paired combination to identify mild AD | 79     | -       | 51          | 86    |
| Liguori et al, 2015  | Chemistry assays + ELISA                     | Lactate levels were significantly higher in AD compared with in controls and VaD; higher CSF levels of t-tau and p-tau proteins corresponded to lower lactate levels | 145    | -       | 80          | 87    |
| Vafadar-Isfahani et al, 2012 | Bioinformatic analysis of proteomic profiles | Levels of the biomarker panel, including SPARC-like 1 protein, fibrinogen alpha chain precursor, Aβ, ApoE precursor, serum albumin precursor, keratin type I cytoskeletal 9 and tetranectin were AD>MCI>controls | 33     | 10      | 20          | 88    |
| Wildsmith et al, 2014 | Targeted proteomics                          | Amyloid precursor protein, neuronal pentraxin receptor, NrCAM and chromogranin A exhibited significant longitudinal changes in AD | 45     | 5       | 10          | 89    |
| Olsson et al, 2013   | ELISA                                        | CSF levels of HFABP were significantly elevated in subjects with AD, and MCI that progressed to AD or VaD | 96     | 170     | 65          | 91    |
| Brys et al, 2009     | Negative ion chemical ionization gas chromatography/mass spectrometry | P-tau (231) is the strongest predictor of the decline from MCI to AD; IP levels uniquely exhibit longitudinal progression effects | -      | 22      | 21          | 94    |
| Ayton et al, 2015    | Myriad Rules Based Medicine platform, Luminex platform | Baseline CSF ferritin levels were negatively associated with cognitive performance, and predicted MCI progression to AD | 67     | 144     | 91          | 95    |

AD, Alzheimer’s disease; MCI, mild cognitive impairment; CSF, cerebrospinal fluid; ELISA, enzyme-linked immunosorbent assay; BBB, blood brain barrier; VaD, vascular dementia; AD7c-NTP, AD-associated neuronal thread protein; NFL, neurofilament; FTD, frontotemporal dementia; GAP 43, growth associated protein 43; sAPP, soluble amyloid precursor proteins; MTLA, medial temporal lobe atrophy; Aβ, amyloid-β; BACE 1, β-secretase; p-, phosphorylated; t-, total; IP, isoprostane; sMRI, structural magnetic resonance imaging; PC-B, Pittsburgh compound-B; VILIP-1, visinin-like protein-1; ApoE, apolipoprotein E; GC-MS, gas chromatography-mass spectrometry; LC-MS/MS, light chromatography-MS/MS; HFABP, heart fatty acid binding protein; Ng, neurogranin; NrCAM, neuronal cell adhesion molecule.
able to secrete or release the protein into the CSF. Post-mortem CSF levels of AD7c-NTP in AD were significantly higher compared with in age-matched controls. The CSF levels of patients with probable AD were also significantly higher compared with controls or other neurological disease controls, and were associated with the severity of cognitive impairment (81). The CSF levels of visinin-like protein-1 (VILIP-1) and the ratios of VILIP-1/Aβ42, similar to tau and tau/AB, may predict future cognitive decline in cognitively normal subjects, differentiate patients with AD from non-AD dementia and healthy controls (82), and predict rates of global cognitive decline in individuals with early AD (83). CSF VILIP-1 levels may also predict rates of whole-brain and regional atrophy with a similar power to CSF levels of tau and p-tau181 in individuals with very mild AD or preclinical AD (84). Longitudinal CSF biomarker patterns, including low Aβ42 in early middle age, markedly increased t-tau, p-tau and VILIP-1 in mid- and late middle age, and increased levels of the neuroinflammatory marker YKL-40 throughout middle age, were useful for screening middle-aged, asymptomatic individuals with AD (85).

Systematic analysis of metabolite profiling of the CSF by magnetic resonance spectroscopy demonstrated that increased cortisol and cysteine levels, and decreased uridine levels, may be involved in the progression of AD. Individuals with severe AD exhibited increased cortisol levels, and individuals with mild AD [Mini Mental State Examination (MMSE)>22] exhibited increased cysteine and decreased uridine levels. Specificity and sensitivity >75% could be obtained for the paired combination of cysteine and uridine to identify mild AD (86). Lactate is a product of glycolytic metabolism; CSF levels of lactate in patients with AD were significantly higher compared with in controls and VaD controls (87). Patients with mild AD exhibited higher lactate levels compared with in moderate and severe AD, and higher lactate levels corresponded with lower levels of t-tau and p-tau. A biomarker panel that analyzed the levels of seven proteins in the CSF by proteomic analysis and mass spectroscopy was able to classify AD individuals from controls with an accuracy of 84.5% (sensitivity 93.3%, specificity 75.7%) (88). Target proteomic analysis detected another four proteins that could reflect obvious longitudinally dynamic alterations during AD progression (89). Other potential CSF-derived markers include α-synuclein, heart fatty acid binding protein (HFABP), PEDF, complexed prostaglandin-d-synthase (PDS) and TTR, isoprostane and ferritin. CSF α-synuclein levels were not only significantly increased in patients with MCI and AD compared with controls, the increase in CSF α-synuclein levels was also significantly associated with the decrease in MMSE scores (90). CSF α-synuclein levels only offered modest sensitivity and specificity as a diagnostic marker of AD. Significantly increased CSF levels of HFABP were detected in patients with AD compared with controls, and in patients with MCI that progressed to AD or VaD when compared with individuals with stable MCI (91). However, HFABP had a lower predictive value than Aβ42, t-tau and p-tau in identifying the progression of MCI to AD and VaD. Cortical neurons and astrocytes in AD brains demonstrated strong immunostaining of PEDF, and CSF PEDF as a biomarker may improve the diagnosis of AD (92). Complexed PDS/TTR exhibited a significant increase in post-mortem ventricular CSF in MCI and late-stage AD compared with diseased control subjects, and lumbar CSF levels of the complex showed a six-fold increase in living subjects with probable AD compared with normal control subjects (93). CSF levels of isoprostane were shown to possess robust longitudinal effects on the progression of MCI to AD. The annual rate of isoprostane was significantly different in the following order: MCI that progressed to AD group>stable MCI group>controls (94). The elevated CSF levels of ferritin were not only associated with cognitive performance but could also predict AD progression (95).

Potential urinary-derived markers for AD and MCI. The potential urinary-derived biomarkers for AD and MCI are presented in Table IV. Patients with AD demonstrated elevated levels of AD7c-NTP in CSF and urine, and the elevated levels of AD7c-NTP were associated with the severity of dementia, i.e., very mild, mild or moderately severe AD. Several studies have suggested that AD7c-NTP is a useful biomarker, and may be widely used to screen the risk of elderly individuals with MCI and AD (96-99).

Analytically, oxidative stress and oxidative DNA damage have important roles in the process of AD. A major product of oxidative DNA damage is 8-hydroxy-2′-deoxyguanosine (8-OhdG). The antioxidant enzyme paraoxonase 1 (PON1) is able to prevent the oxidation of low-density lipoproteins. Patients with AD exhibited significantly elevated levels of 8-OhdG in urine and significantly decreased PON1 activity in serum, as compared with in healthy elderly volunteers (100). Isoprostanes, which are products of arachidonic acid peroxidation by free radicals, are also biomarkers for oxidative injury. Urinary levels of F2-isoprostanes are significantly elevated in AD subjects (101). In addition, 3-hydroxypropyl mercapturic acid/creatinine reduction in urine is not only associated with stroke but is also an ideal biomarker for differentiating patients with AD from patients with MCI (102). Furthermore, high levels of urinary polyphenols may exert protective effects of polyphenol intake against cognitive impairment, and are associated with a lower risk of obvious cognitive decline in elderly individuals over a 3-year follow-up period (103).

Cell-based techniques for analyzing tau pathogenicity. Recently, two novel methods to detect tau pathogenicity have been developed. One method detects tau seeding activity in various AD brain lysates using a cell-based biosensor assay. In vitro studies have reported that pathogenic tau oligomers can move between cells similar to mechanisms of prion pathogenesis, this is referred to as transcellular spread (104). Briefly, biosensor cells are generated to express human tau proteins fused with cyan fluorescent protein (CFP) or yellow fluorescent protein (YFP); when pathogenic tau from AD samples is added to a culture of biosensor cells, which contain tau proteins fused with CFP or YFP, pathogenic tau promotes the aggregation of two fused proteins and results in a positive fluorescence resonance energy transfer signal (105). The signal intensity reflects the pathogenic tau seeding activity of the AD sample. Detection of pathogenic tau seeding activity from human brain samples could reliably differentiate AD from Huntington's disease and aged controls (106). In addi-
| Study | Methods | Identified biomarkers | Control (n) | MCI (n) | AD (n) |
|-------|---------|----------------------|------------|---------|--------|
| Ghahropour et al., 2008 | ELISA | Higher urinary AD7c-NTP in AD | 134 | 66 | 66 |
| Kim et al., 2010 | HPLC-ECD | Higher AD7c-NTP levels in MCI | 60 | 60 | 45 |
| Zengi et al., 2011 | HPLC-ECD | Urinary 8-OHdG level | 74 | - | 22 |
| Yoshida et al., 2015 | LC-MS/MS | PGF (2 alpha) was the most reliable biochemical marker to distinguish AD from MCI | 74 | - | 22 |
| Rabassa et al., 2015 | F-C assay | High concentrations of polyphenols were associated with a lower risk of cognitive decline (dementia-free) | 103 | - | - |

**Table IV. Possible urinary-derived markers for identifying risk of MCI and AD.**

**AD, Alzheimer's disease; MCI, mild cognitive impairment; ELISA, enzyme-linked immunosorbent assay; AD7c-NTP, AD-associated neuronal thread protein; GC-MS, gas chromatography-mass spectrometry; HPLC-ECD, high-performance liquid chromatography-electrochemical detection; 8-OHdG, 8-hydroxy-2'-deoxyguanosine; PON1, paraoxonase/arylesterase 1; LC-MS/MS, liquid chromatography-mass spectrometry; PGF (2 alpha), prostaglandin F (2 alpha); 3-HPMA/Creat, 3-hydroxypropyl mercapturic acid/creatinine; F-C, Folin-Ciocalteu.**

Implications for CF screening. Aging-related major neurocognitive disorders, particularly AD-induced neurodegeneration, can progress over decades before clinical symptoms become apparent. Biomarkers for brain pathological processes allow for their early diagnosis in preclinical stages and for the development of objective prognostic assessments in clinical intervention trials. Some fluid biomarkers, including Aβ42, t-tau and p-tau, have been widely used in clinical practice and clinical trials. The development of novel measurement techniques greatly promotes the production of novel biomarkers and improves the accuracy of old biomarkers (19,20,73,74). Several novel biomarkers associated with different aspects of AD neuropathology are being developed, including those related to synaptic dysfunction, neuronal damage and apoptosis, neuronal activity alteration, neuroinflammation, oxidative stress, metabolites, mitochondrial function and aberrant lipid metabolism. A bioinformatics approach for identifying specific single nucleotide polymorphisms (108-110) and epigenetic markers, including microRNAs (111) in the CSF or blood of patients with MCI, AD or non-AD dementia may also be useful for AD diagnosis and differentiation.

Based on the ordering of AD biomarkers, particularly CSF biomarkers (Aβ42, t-tau and p-tau), and AD-associated biomarkers, such as neural injury and neuroinflammation biomarkers, we classified which one was the earliest event resulting in the heterogeneity of cognitive impairment. These biomarkers may be helpful for the diagnosis of CF and the differential diagnosis of cognitive impairment from CF, including AD or VaD. CF consists of reversible and potentially reversible cognitive impairment subtypes (112). The former is based on SCD, and the latter is comparable to MCI. The most common cause of cognitive impairment of CF is AD. The severity of SCD has been associated with biomarkers for AD in subjects with MCI, including low CSF Aβ42 and high CSF tau or p-tau levels (46). Longitudinal CSF biomarkers, such as Aβ42 reductions in early middle age; markedly increased tau, p-tau and VILIP-1 in mid- and late middle age, and increases in YKL-40 throughout middle age were associated with the

P301S tau transgenic mice demonstrated that tau seeding activity is an ideal biomarker of tauopathy. Increases in tau seeding activity occurred 1.5 months earlier than tau deposition. Future verification of pathogenic tau seeding activity in human CSF or blood will improve the diagnostic accuracy of tauopathies in a clinical setting, and provide a noninvasive biomarker to evaluate the therapeutic efficacy of tau-modifying agents in future clinical trials.

The second method quantitatively detects tau pathogenicity in biological samples using monoclonal antibodies against seeding tau. The antibodies can also be used as an immunotherapy that traps pathogenic tau and prevents transcellular spread. Anti-pathogenic tau antibodies that inhibit the ability for tau pathogenicity *in vitro* could markedly reduce the levels of p-tau, aggregated and insoluble tau, and inhibit microglial activation and improve cognition in P301S tau transgenic mice (107). If these antibodies can be used to quantify tau pathogenicity in CSF and blood from different individuals, they may be considered potentially noninvasive biomarkers for detecting tau pathology.
severity of cognitive impairment in preclinical AD (85). The combination of fluid biomarkers and imaging biomarkers could further improve diagnostic accuracy of cognitive impairment. In addition, physical frailty and AD may share similar pathophysiological mechanisms. Certain AD-associated fluid biomarkers, such as oxidative stress and inflammatory markers, may also contribute to the screening of physical frailty in CF subjects (112,113). Furthermore, the dynamic changes of AD-specific and AD-associated fluid biomarkers may be helpful for the screening of candidate drugs that affect cognitive impairment and physical frailty.

Acknowledgements

The present study was supported by grants from the Shanghai Hospital Development Center (grant no. SHDC12014221) and the Shanghai Key Laboratory of Clinical Geriatric Medicine (grant no. 13dz2260700).

References

1. Kelaiedy E, Cesari M, Canevelli M, van Kan GA, Ousset PJ, Gillette-Guyonet S, Ritz P, Duveaux F, Soto ME, Proencher V, et al: Cognitive frailty: Rational and definition from an (I.A.N.A./I.A.G.G.) international consensus group. J Nutr Health Aging 17: 726-734, 2013.
2. Ruan Q, Yu Z, Chen M, Bao Z, Li J and He W: Cognitive frailty, a novel target for the prevention of elderly dependency. Ageing Res Rev 20: 1-10, 2015.
3. Buerger K, Frisoni G, Uspenskaya O, Ewers M, Zetterberg H, Geroldi C, Binetti G, Johannsen P, Rossini PM, Wahlund LO, et al: Validation of Alzheimer's disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimer's disease neuroimaging initiative (E-ADNI). Exp Gerontol 44: 579-585, 2009.
4. Yang T, Hong S, O'Malley T, Sperring RA, Walsh DM and Selkoe DJ: New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF. Alzheimers Dement 9: 99-112, 2013.
5. Dixon-Woods M, Agarwal S, Jones D, Young B and Sutton A: Synthesising qualitative and quantitative evidence: A review of possible methods. J Health Serv Res Policy 10: 45-53, 2005.
6. Harries K and Macaitis K: A move to more systematic and transparent approaches in qualitative evidence synthesis: Update on a review of published papers. Qual Res 12: 402-442, 2012.
7. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, et al: The diagnosis of dementia due to Alzheimer's disease: Recommendations from the national institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 263-269, 2011.
8. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, et al: The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the national institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 270-279, 2011.
9. Barnett-Page E and Thomas J: Methods for the synthesis of qualitative research: A critical review. BMC Med Res Methodol 9: 59, 2009.
10. Grant MJ and Booth A: A typology of reviews: An analysis of 14 review types and associated methodologies. Health Info Lib J 26: 91-108, 2009.
11. Noel-Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ, Davis D, Quinn TJ, Hyde C, Rutjes AW, et al: Reporting standards for studies of diagnostic test accuracy in dementia: The STAR*Drem Inititative. Neurology 83 : 364-373, 2014.
12. Padovani A, Borroni B, Colciaghi F, Pettenati C, Cottini E, Agosti C, Lenzi GL, Caltagirone C, Trabucchi M, Cattabeni F and Di Luca M: Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. Arch Neurol 59: 71-75, 2002.
13. Borroni B, Colciaghi F, Caltagirone C, Rozzini L, Broglio L, Cattabeni F, Di Luca M and Padovani A: Platelet amyloid precursor protein abnormalities in mild cognitive impairment predict conversion to dementia of Alzheimer type: A 2-year follow-up study. Arch Neurol 60: 1740-1744, 2003.
14. Baskin F, Rosenberg RN, Iyer L, Hynan L and Cullum CM: Platelet APP isoform ratios correlate with declining cognition in AD. Neurology 54: 1907-1909, 2000.
15. Mosdon CI, Ross ED, Stoner JA, Cowan LD, Vincent AS and Dale GL: Coated-platelet levels and progression from mild cognitive impairment to Alzheimer disease. Neurology 76: 247-252, 2011.
16. Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, Bürger K, Hampel H, Fröhlich L, et al: Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. Exp Neurol 223: 366-370, 2010.
17. Groul ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, Rosand J, Growdon JH and Greenberg SM: Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 66: 23-29, 2006.
18. Lopez OL, Kuller LH, Mehta PD, Becker JT, Gach HM, Sweet RA, Chang YF, Tracy R and DeKosky ST: Plasma amyloid levels and the risk of AD in normal subjects in the cardiovascular health study. Neurology 83: 352-359, 2014.
19. Risdin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, Piech T, Patel P, Chang L, Rivnak AJ, et al: Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 28: 598-599, 2010.
20. Zetterberg H, Wilson D, Andreasen U, Minthon L, Blesson K, Randall J and Hansson O: Plasma tau levels in Alzheimer's disease. Alzheimers Res Ther 5: 9, 2013.
21. Zhang Z, Song M, Liu X, Kang SS, Kwon IS, Duong DM, Seyfried NT, Hu WT, Liu Z, Wang ZJ, et al: Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. Nat Med 20: 1254-1262, 2014.
22. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, Hall WJ, Fisher SG, Peterson DR, Haley JM, et al: Plasma phosphothreonin identifies antecedent memory impairment in older adults. Nat Med 20: 415-418, 2014.
23. Whiley L, Sen A, Heaton J, Brogoiti S, García-Gómez D, Leung R, Smith N, Thambisetty M, Kloszweska I, Mecacci P, et al: Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiol Aging 35: 271-279, 2014.
24. Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH and Wurtman RJ: Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci USA 89: 1671-1675, 1992.
25. Marksteiner J, Imariaghe D, Defrancesco M, Deisenhammer EA, Kemmler G and Humpel C: Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: A pilot-study. Exp Gerontol 50: 114-121, 2014.
26. Hye A, Kiddoch-Contrares J, Baird AL, Ashton NJ, Bazenet C, Leung R, Westman E, Simmons A, Dobson R, Sattlecker M, et al: Plasma protein spectins: prediction of cognitive status from preclinical and mild cognitive impairment: Alzheimers Dement 10: 799-807, 2014.
27. Lane R, Feldman HH, Meyer J, He Y, Ferris SH, Nordberg A, Darreh-Shori T, Soininen H, Pirttilä T, Farlow MR, et al: Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenomics Genomics 18: 298-298, 2008.
28. Soares HD, Potter WZ, Pickering E, Kuhn M, Immernann FW, Shera DM, Ferr M, Dean RA, Simon AJ, Swenson F, et al: Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol 69: 1310-1317, 2012.
29. Sattlecker M, Kiddle SJ, Newhouse S, Protsi P, Nelson S, Williams S, Johnston C, Kiilkic R, Simmons A, Westman E, et al: Alzheimer’s disease biomarker discovery using SOMAnscan multiplexed protein technology. Alzheimers Dement 10: 724-734, 2014.
48. Landau SM, Lu M, Joshi AD, Pontecorvo M, Minton MA, Trojanowski JQ, Shaw LM and Jagust WJ; Alzheimer’s Disease Neuroimaging Initiative: Comparing position emission tomography and cerebrospinal fluid measurements of β-amyloid. Ann Neurol 74: 826-836, 2013.

49. Nettiksimmons J, Harvey D, Brewer J, Carmichael O, DeCarli C, Jack CR Jr, Petersen R, Shaw LM, Trojanowski JQ, Weiner MW, et al: Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline Neurology 74: 1419-1428, 2010.

50. Okonkwo OC, Alosco ML, Griffth HR, Miecke MM, Shaw LM, Trojanowski JQ and Tremont G: Alzheimer’s Disease Neuroimaging Initiative: Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum. Neurology 77: 1801-1807, 2011.

51. Mattsson N, Zetterberg H, Hansson O, Andreassen A, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, et al: CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302: 385-393, 2009.

52. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR Jr, et al: Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75: 230-238, 2010.

53. Van Rossum EA, Vos SJ, Burns L, Knol DL, Scheltens P, Soininen H, Wahlund LO, Hampel H, Toslaki M, Minthon L, et al: Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology 79: 1809-1816, 2012.

54. Vemuri P, Wisin HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC and Jack CR Jr; Alzheimer’s Disease Neuroimaging Initiative: MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change. Neurology 73: 294-301, 2009.

55. Eckerström C, Olsson E, Bjerke M, Malmgren H, Edman A, Wallin A and Nordlund A: A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia. J Alzheimers Dis 36: 421-431, 2013.

56. Shaffer JL, Petrella JR, Sheldon FC, Choudhury KR, Calhoun VD, Coleman RE and Doraiswamy PM; Alzheimer's Disease Neuroimaging Initiative: Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinalfluid, MR imaging, and PET biomarkers. Radiology 266: 583-591, 2013.

57. Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR Jr, Feldman HH, Bokde AL, Alexander GE, Scheltens P, et al: Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiology Aging 33: 1203-1214, 2012: Predicting conversion from mild cognitive impairment to Alzheimer’s disease.

58. Vemuri P, Wisin HJ, Weigand SD, Knopman DS, Trojanowski JQ, Shaw LM, Bernstein MA, Aisen PS, Weiner M, Petersen RC, et al: Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology 73: 143-151, 2010.

59. Blennow K, Wallin A, Fredman P, Karlsson I, Gottfries CG and Svennerholm L: Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol Scand 81: 323-326, 1990.

60. Skoog I, Wallin A, Fredman P, Hesse C, Aervasson O, Karlsson I, Gottfries CG and Blennow K: A population study on blood-brain barrier disruption in 85-89 year olds and its relation to Alzheimer's disease and vascular dementia. Neurology 50: 966-971, 1998.

61. Halliday MR, Polmarra N, Sagare AP, Mack WJ, Frangione B and Zlokovic BV: Relationship between cycliphenil a levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein e4 carriers and blood-brain barrier breakdown. JAMA Neurol 70: 1198-1200, 2013.

62. Matsumoto Y, Yamase D, Noguchi-Shinohara M, Ono K, Yoshita M and Yamada M: Blood-brain barrier permeability correlates with the terminal local deoxygenation atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease. Dement Geriatr Cogn Disord 23: 241-245, 2007.

63. Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhou RZ, Toga AW, Bassett S, Liu CY, Amezcua L, et al: Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85: 296-302, 2015.
dementia, reflecting a common pathophysiological process.

Edman A, Vanmechelen E, Wallin A and Blennow K; Alzheimer's Disease Neuroimaging Initiative: Cerebrospinal fluid levels of the Abeta42/Abeta40 ratio in patients with mild cognitive impairment. JAMA Neurol 72: 1029-1042, 2015.

Czech C, Berndt P, Busch K, Schmitz O, Wiemer J, Most V, Hampel H, Kastler J and Senn H: Metabolite profiling of Alzheimer's disease cerebrospinal fluid. PLoS One 7: e31501, 2012.

Liguori C, Stefani A, Sancesario G, Sancesario GM, Marciani MG and Pierantozzi M: CSF lactate levels, τ proteins, cognitive decline: A dynamic relationship in Alzheimer's disease. J Neurol Neurosurg Psychiatry 86: 655-665, 2015.

Vafadar-Ijfasahi B, Ball G, Coveney C, Lemetre B, Boocock D, Minthon L, Hansson O, Nislund L, Nordberg A, Jönsson S and Hedman J: Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid. J Alzheimers Dis 28: 625-636, 2012.

Wildsmith KR, Schauer SP, Mathis AM, Arnott D, Zhu Y, Haznedar J, Kaur S, Mathews WR and Honigberg LA: Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics. Mol Neurodegener 9: 22, 2014.

Korff A, Liu C, Ginthinha C, Shi M and Zhang J; Alzheimer's Disease Neuroimaging Initiative: α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment. J Alzheimers Dis 36: 679-688, 2013.

Olsson B, Hertz J, Ohlsson M, Nägga K, Höglund K, Basun H, Annas P, Lannfelt L, Andreasen N, Minthon L, et al: Cerebrospinal fluid levels of heart fatty acid binding protein in AD7C-NTP cDNA expression in Alzheimer's disease and cognitive impairment. J Alzheimers Dis 34: 673-679, 2013.

Yamaguchi S, Inukai T and Nakajima N: Is pigment epithelium-derived factor involved in cerebrospinal fluid a promising biomarker for early diagnosis of Alzheimer's disease? Med Hypotheses 63: 115-117, 2004.

Lovell MA, Lynch BC, Xiong S, Quinn JF, Kaye J and Markesbery WR: An aberrant protein complex in CSF as a biomarker of Alzheimer disease. Neurology 70: 2212-2218, 2008.

Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, et al: Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiology Aging 30: 682-690, 2009.

Aytton S, Faux NG and Bush AI; Alzheimer's Disease Neuroimaging Initiative: Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. Nat Commun 6: 7660, 2015.

Ghanbari H, Ghanbari K, Beschiti I, Munzar M, Vasaukas A and Averbach P: Biochemical assay for AD7C-NTP in urine as an Alzheimer's disease marker. J Clin Lab Anal 10: 285-288, 1998.

Goodman I, Golden G, Flitman S, Xie K, McConville M, Levy S, Zimmerman E, Lebedeva Z, Richter R, Minagar A and Averbach P: A multi-center blinded prospective study of urine neural thread protein measurements in patients with suspected Alzheimer's disease. J Am Med Dir Assoc 8: 21-30, 2007.

de la Monte SM and Wands JR: The AD7C-ntp neural thread protein biomarker for detecting Alzheimer's disease. Front Biosci 7: d989-d996, 2002.
99. Ma L, Chen J, Wang R, Han Y, Zhang J, Dong W, Zhang X, Wu Y and Zhao Z: The level of Alzheimer-associated neuronal thread protein in urine may be an important biomarker of mild cognitive impairment. J Clin Neurosci 22: 649-652, 2015.

100. Zengi O, Karakas A, Ergun U, Senes M, Inan L and Yucel D: Urinary 8-hydroxy-2′-deoxyguanosine level and plasma paraoxonase 1 activity with Alzheimer's disease. Clin Chem Lab Med 50: 529-534, 2011.

101. Kim KM, Jung BH, Paeng KJ, Kim I and Chung BC: Increased urinary F(2)-isoprostanes levels in the patients with Alzheimer's disease. Brain Res Bull 64: 47-51, 2004.

102. Yoshida M, Higashi K, Kuni K, Mizo M, Saiki R, Nakamura M, Waragai M, Uemura K, Toida T, Kashiwagi K and Igashiki K: Distinguishing mild cognitive impairment from Alzheimer's disease with acrolein metabolites and creatinine in urine. Clin Chim Acta 441: 115-121, 2015.

103. Rabassa M, Cherubini A, Zamora-Ros R, Urpi-Sarda M, Bandinelli S, Ferrucci L and Andres-Lacueva C: Low levels of a urinary biomarker of dietary polyphenol are associated with substantial cognitive decline over a 3-year period in older adults: The invecchiare in chianti study. J Am Geriatr Soc 63: 938-946, 2015.

104. Cook CN, Murray ME and Petrucelli L: Understanding biomarkers of neurodegeneration: Novel approaches to detecting tau pathology. Nat Med 21: 219-220, 2015.

105. Kfoury N, Holmes BB, Jiang H, Holtzman DM and Diamond MI: Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem 287: 19440-19451, 2012.

106. Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, Belaygorod L, Cairns NJ, Holtzman DM and Diamond MI: Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci USA 111: E4376-E4385, 2014.

107. Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI and Holtzman DM: Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80: 402-414, 2013.

108. Kong D, Giovanello KS, Wang Y, Lin W, Lee E, Fan Y, Murali Doraiswamy P and Zhu H: Predicting Alzheimer's disease using combined imaging-whole genome SNP data. J Alzheimers Dis 46: 695-702, 2015.

109. Sun Y, Bresell A, Rantalainen M, Höglund K, Lebouvier T and Salter H: Alzheimer Disease Neuroimaging Initiative: An integrated bioinformatics approach for identifying genetic markers that predict cerebrospinal fluid biomarker p-tau181/Ab1-42 ratio in ApoE4-negative mild cognitive impairment patients. J Alzheimers Dis 45: 1061-1076, 2015.

110. Castro-Chavira SA, Fernandez T, Nicolini H, Diaz-Cintra S and Prado-Alcala RA: Genetic markers in biological fluids for aging-related major neurocognitive disorder. Curr Alzheimer Res 12: 200-209, 2015.

111. Femminella GD, Ferrara N and Rengo G: The emerging role of microRNAs in Alzheimer's disease. Front Physiol 6: 40, 2015.

112. Namioka N, Hanyu H, Hirose D, Hatanaka H, Sato T and Shimizu S: Oxidative stress and inflammation are associated with physical frailty in patients with Alzheimer’s disease. Geriatr Gerontol Int: Jun 14, 2016 (Epub ahead of print).

113. Panza F, Solfirizzi V, Barulli MR, Santamato A, Seripa D, Pilotto A and Logroscino G: Cognitive Frailty: A systematic review of epidemiological and neurobiological evidence of an age-related clinical condition. Rejuvenation Res 18: 389-412, 2015.